Alcalay Roy N, Levy Oren A, Wolf Pavlina, Oliva Petra, Zhang Xiaokui Kate, Waters Cheryl H, Fahn Stanley, Kang Un, Liong Christopher, Ford Blair, Mazzoni Pietro, Kuo Sheng, Johnson Amelie, Xiong Lan, Rouleau Guy A, Chung Wendy, Marder Karen S, Gan-Or Ziv
Department of Neurology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
Biologics Structural and Functional Research, Biopharmaceutics Development, Genzyme, a Sanofi company, Framingham, MA, USA.
NPJ Parkinsons Dis. 2016;2:16004-. doi: 10.1038/npjparkd.2016.4. Epub 2016 Mar 10.
Mutations in glucocerebrosidase () are a common risk factor for Parkinson's disease (PD). The scavenger receptor class B member 2 () gene encodes a receptor responsible for the transport of glucocerebrosidase (GCase) to the lysosome. Two common SNPs in linkage disequilibrium with , rs6812193 and rs6825004, have been associated with PD and Lewy Body Disease in genome wide association studies. Whether these SNPs are associated with altered glucocerebrosidase enzymatic activity is unknown. Our objective was to determine whether SNPs are associated with PD and with reduced GCase activity. The gene was fully sequenced, and the G2019S and rs6812193 and rs6825004 SNPs were genotyped in 548 PD patients and 272 controls. GCase activity in dried blood spots was measured by tandem mass spectrometry. We tested the association between genotypes and PD risk in regression models adjusted for gender, age, and G2019S and mutation status. We compared GCase activity between participants with different genotypes at rs6812193 and rs6825004. Genotype at rs6812193 was associated with PD status. PD cases were less likely to carry the T allele than the C allele (OR=0.71; p=0.004), but GCase enzymatic activity was similar across rs6812193 genotypes (C/C: 11.88 μmol/l/h; C/T: 11.80 μmol/l/h; T/T: 12.02 μmol/l/h; p=0.867). Genotype at rs6825004 was not associated with either PD status or GCase activity. In conclusion, our results support an association between genotype at rs6812193 and PD, but suggest that the increased risk is not mediated by GCase activity.
葡萄糖脑苷脂酶()突变是帕金森病(PD)的常见风险因素。清道夫受体B类成员2()基因编码一种负责将葡萄糖脑苷脂酶(GCase)转运至溶酶体的受体。在全基因组关联研究中,与处于连锁不平衡状态的两个常见单核苷酸多态性(SNP),即rs6812193和rs6825004,已被发现与PD和路易体病相关。尚不清楚这些SNP是否与葡萄糖脑苷脂酶活性改变有关。我们的目的是确定这些SNP是否与PD以及GCase活性降低有关。对基因进行了全序列测定,并在548例PD患者和272名对照中对G2019S以及rs6812193和rs6825004这两个SNP进行了基因分型。通过串联质谱法测定干血斑中的GCase活性。我们在针对性别、年龄以及G2019S和突变状态进行校正的回归模型中,检验了基因型与PD风险之间的关联。我们比较了rs6812193和rs6825004不同基因型参与者之间的GCase活性。rs6812193的基因型与PD状态相关。PD病例携带T等位基因的可能性低于携带C等位基因(比值比=0.71;p=0.004),但rs6812193各基因型的GCase酶活性相似(C/C:11.88μmol/(l·h);C/T:11.80μmol/(l·h);T/T:12.02μmol/(l·h);p=0.867)。rs6825004的基因型与PD状态或GCase活性均无关。总之,我们的结果支持rs6812193处的基因型与PD之间存在关联,但表明风险增加并非由GCase活性介导。